Harbin Pharmaceutical Group Co., Ltd.
Harbin Pharmaceutical Group Co., Ltd., commonly referred to as Harbin Pharma, is a leading player in the pharmaceutical industry, headquartered in Harbin, China. Established in 1997, the company has made significant strides in the development and production of a wide range of pharmaceutical products, including traditional Chinese medicine, chemical drugs, and biopharmaceuticals. With a strong presence in both domestic and international markets, Harbin Pharma is renowned for its commitment to innovation and quality. The company’s core offerings include prescription medications, over-the-counter products, and health supplements, distinguished by their efficacy and adherence to stringent safety standards. Recognised for its robust research and development capabilities, Harbin Pharmaceutical Group has achieved notable milestones, positioning itself as a trusted name in healthcare. Its dedication to advancing medical solutions continues to enhance its reputation within the global pharmaceutical landscape.
DitchCarbon Score
How does Harbin Pharmaceutical Group Co., Ltd.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Harbin Pharmaceutical Group Co., Ltd.'s score of 22 is lower than 83% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Harbin Pharmaceutical Group Co., Ltd.'s reported carbon emissions
Harbin Pharmaceutical Group Co., Ltd., headquartered in China (CN), currently does not report any specific carbon emissions data, as there are no available figures for emissions in kg CO2e. Additionally, the company has not established any documented reduction targets or climate pledges, indicating a lack of formal commitments towards reducing its carbon footprint. As of now, there are no emissions inherited from a parent or related organization, and the company does not participate in initiatives such as the Science Based Targets initiative (SBTi) or the Carbon Disclosure Project (CDP) that could provide further insights into its climate commitments. In the absence of specific emissions data and reduction initiatives, Harbin Pharmaceutical Group's climate strategy remains unclear, highlighting a potential area for development in corporate sustainability practices.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Harbin Pharmaceutical Group Co., Ltd. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
